VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The impact of BCL7A loss on myeloma cell growth and future therapeutic strategies

Chandraditya Chakraborty, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the impact of BCL7A loss on myeloma cell growth, and further explains how better understanding the interaction between BCL7A and other genes may allow therapeutic targets to be developed. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter